The primary objective of this trial is to assess the safety of an uninterrupted dabigatran etexilate periprocedural anticoagulant regimen compared to an uninterrupted warfarin regimen in Non-Valvular Atrial Fibrillation (NVAF) patients undergoing Atrial Fibrillation (AF) ablation in a PROBE (Prospective, randomized, open label, blinded end point) active controlled study.
[button title=”Read Study” link=”https://clinicaltrials.gov/study/NCT02348723″ target=”_blank” align=”” icon=”” icon_position=”” color=”” font_color=”” size=”2″ full_width=”” class=”” download=”” rel=””]